Objectives Hypertension and/or antihypertensive medication are reported to be risk factors of renal cell carcinoma (RCC). We investigated whether these risk factors are associated with von Hippel-Lindau gene (VHL) mutations in RCC.
Introduction
Hypertension and use of diuretics or other antihypertensive medication have been found to be risk factors for renal cell carcinoma (RCC) in many epidemiological studies [1, 2] . It is unclear, however, whether the increased risk is caused by hypertension itself, or by the use of antihypertensive medication. Some recent studies showed that diuretic medication was no longer a risk factor after controlling for the diagnosis of hypertension [3, 4] , suggesting that not medication but hypertension is a risk factor for RCC. Several prospective studies have studied the effect of hypertension on the risk of RCC [5] [6] [7] [8] [9] [10] [11] [12] , but few prospective cohort studies were also able to study the use of antihypertensive medication [8, 11, 12] .
RCC is classified in different subtypes. The majority of RCC are of the clear-cell type (80%); other subtypes are papillary RCC (10%), chromophobe RCC (5%), collecting-duct carcinoma (1%) and unclassified RCC (3-5%) [13] . Von Hippel-Lindau disease (VHL) is a rare inherited disorder associated with (amongst others) an increased risk for clear-cell RCC [14] . After the identification of the VHL gene on chromosome 3p25, it became evident that this gene is also involved in the development of sporadic clear-cell RCC. It is estimated that approximately 75% of all sporadic clear-cell RCCs harbour bi-allelic VHL defects [15] . Two studies suggested that risk factors, such as occupational exposure to trichloroethylene and fruit consumption, are associated with mutations in the VHL gene in RCC [16, 17] .
Despite the fact that many studies have observed an association between the diagnosis of hypertension and/or use of antihypertensive medication and RCC risk, there is still much uncertainty with respect to the biological mechanism. Gago-Dominguez [18] suggested the 'lipid peroxidation' hypothesis as the underlying mechanism, but this remains to be proven. The different subtypes of RCC may have different aetiologies. The VHL gene is the main causative gene for sporadic clear-cell RCC [15] . Whether hypertension and/or use of antihypertensive medication are associated with clear-cell RCC, or more specifically with mutational status of the VHL gene, has not been investigated before. It is conceivable that these risk factors are associated with specific subtypes of RCC, or with mutational status of the VHL gene in clear-cell RCC.
We decided to study whether hypertension and use of antihypertensive medication were associated with risk of RCC, and more specifically with mutational status of the VHL gene in clear-cell RCC, within a large prospective cohort study.
Materials and methods

Subjects
The Netherlands Cohort Study on diet and cancer is a prospective cohort study, which started in September 1986. The study design has been reported in detail elsewhere [19] . Briefly, the cohort included 120 852 men and women, aged 55-69 years, at the beginning of the study. The study was designed as a case-cohort study, using all cases and a random sample of 5000 persons from the cohort (subcohort), who have been followed to estimate the accumulated person-years in the entire cohort [20] . Follow-up for incident cancer has been established by computerized record linkage with the Netherlands Cancer Registry (NCR) and PALGA, a national database of pathology reports. The method of record linkage to obtain information on cancer incidence has been described previously [21] . The completeness of cancer follow-up was estimated to be more than 96% [22] . From 1986 to 1997 (11.3 years follow-up) 355 kidney cancer cases [International Classification of Diseases for Oncology, version 3 (ICD-O-3): C64.9] were identified. Urothelial cell carcinomas were excluded and only histologically confirmed epithelial cancers were included (ICD-O: M8010-8119, 8140-8570), leaving 337 cases. All subcohort members who reported prevalent cancer (excluding skin cancer) at baseline were excluded from analyses (leaving 4774 subcohort members).
VHL mutation analysis
Paraffin blocks of tumours were collected from 51 pathology laboratories, the procedures have been described in detail elsewhere [23] . We were able to collect material for 251 cases. One experienced pathologist (C.A.H.K.) revised all haematoxylin and eosin (HE)-stained slides. The RCCs were classified according to the World Health Organization (WHO) Classification of Tumours, 2002 [24] . The protocol for DNA isolation and mutation analyses have been described previously [23] . Briefly, paraffin was removed with xylene and tumour DNA was extracted by salt precipitation. The entire gene was amplified using six primer sets, as described before [23] . Samples were first subjected to polymerase chain reaction-single-strand conformational polymorphism (PCR-SSCP) analysis, which was followed by direct sequencing in the case of aberrant or unclear results. Mutations were identified by visual inspection of sequences provided by the ABI basecaller (Applied Biosystems, Nieuwerkerk a.d. IJssel, The Netherlands). After revision and VHL gene mutation analyses, data were available for 235 cases [23] .
Questionnaire
At baseline, all cohort members completed a mailed, selfadministered questionnaire on dietary habits and other risk factors for cancer [25] . Participants were asked to report whether a physician had ever diagnosed 'high blood pressure' and at what age the diagnosis was made (in 5-year age groups from 'younger than 30 years', 30-34 years' to '65-69 years'). Duration since diagnosis was calculated by subtracting the midpoint age in the age group of diagnosis from the age at baseline and was categorized into three broad categories: 0-9 years, 10-19 years and 20 years.
Participants were also asked to report on use of any drugs that they used longer than 6 months, for what condition and in what calendar period. All drugs were classified into therapeutic groups using the Anatomical Therapeutic Chemical (ATC) classification of the WHO Collaborative Centre for Drug Statistical Methodology [26, 27] .
Data analysis
Differences between cases with and without collected tumour material were assessed by calculating Student t-tests and chi-squared tests. RRs for RCC were calculated for history of hypertension and use of antihypertensive medication. Case groups were defined as follows: total RCC (all histologically confirmed cases of RCC detected by linkage to cancer and pathology registries; n ¼ 337); clear-cell RCC (classified as clear-cell RCC after pathological revision; n ¼ 187); mutated clear-cell RCC (clear-cell RCC with a mutation in the VHL gene; n ¼ 114) and wild-type clear-cell RCC (clear-cell RCC without a mutation in the VHL gene; n ¼ 73). Confounders considered were age at baseline (years), sex, current cigarette smoking (yes/no), cigarettes smoked (number/ day), years of cigarette smoking (years), alcohol consumption (g/day), body mass index (BMI; kg/m 2 ), a history of diabetes mellitus (yes/no), a history of RCC in first-grade family (yes/no), non-occupational physical activity (<30, 30-60, 60-90, >90 min/day), occupational physical activity for men only (<8, 8-12, >8 kJ/min) and socioeconomic status (SES) based on education. Those variables that were associated with diagnosis of hypertension (and/or use of antihypertensive medication), that were an independent risk factor of RCC and that changed the risk estimates for the association of hypertension (and/or the use of antihypertensive medication) and RCC more than 10% were included as confounders in multivariable analyses. Using these criteria, confounders entered in the analyses were age, sex, BMI, current cigarette smoking, number of cigarettes smoked per day, and number of years of cigarette smoking.
RRs and corresponding 95% confidence intervals (CI) for RCC were estimated using Cox proportional hazard models processed with the STATA statistical software package (STATA statistical software, Release 7; STATA Corporation, College Station, Texas, USA; 2001), after testing the proportional hazards assumption using scaled Schoenfeld residuals [28] . Standard errors were estimated using the robust Huber-White sandwich estimator to account for additional variance introduced by sampling person-time from the cohort [29] . To obtain P values for dose-response trends, ordinal exposure variables were fitted as continuous terms.
Results
Hypertension was reported somewhat more frequently among RCC cases than among subcohort members (29.4 versus 26.3%; Table 1 ). RCC cases also reported a slightly higher use of antihypertensive medication than
Hypertension and VHL-mutations in RCC Schouten et al. 1999 Table 1 Description of exposure variables and potential confounders in subcohort members (N U 4774), RCC cases (N U 337) and RCC cases with tissue blocks collected (N U 235), The Netherlands Cohort Study on Diet and Cancer (NLCS) 1986-1997 Studying the interaction of the diagnosis of hypertension and antihypertensive medication use did not reveal divergent results. The RRs for use of diuretics or beta-blockers in cohort members, who had not reported a diagnosis of hypertension, were relatively high, but the number of cases and person-years in the subcohort was small ( Table 2 ).
Repeated analysis with exclusion of the first 2 years of follow-up did not alter the results considerably: RRs were slightly lower (data not shown).
Of the 235 patients for whom tissue specimens were available, 187 had a clear-cell RCC (80%). In 114 patients with clear-cell RCC a mutation in the VHL gene was detected (61%). The RR for diagnosis of hypertension was higher in cases with a VHL mutation than in cases with VHL wild type: RRs 1.34 (95% CI, 0.87-2.07) and 0.88 (95% CI, 0.51-1.53), respectively (Table 3) . By contrast, the RR for use of antihypertensive medication was higher in cases with VHL wild type: RR ¼ 1.53 (95% CI, 0.89-2.61). The RR for use of diuretics was statistically significantly increased in cases with VHL wild type, RR ¼ 2.11 (95% CI, 1.16-3.83).
The RR was also increased in cohort members who used diuretics or beta-blockers and did not report a diagnosis of hypertension but, as in total RCC, numbers of cases and subcohort person-years were very small and the confidence intervals were wide.
Discussion
In this study we observed that hypertension and use of anti-hypertensive medication were associated with a slightly increased, although statistically non-significant, risk of RCC. The association with hypertension was stronger in RCC patients with VHL mutations, while the association with use of antihypertensive medication was stronger in cases with VHL wild type. Diuretics were associated with an increased risk of clear-cell RCC with VHL wild type.
These results from the Netherlands Cohort Study on Diet and Cancer are most likely not affected by selection or information bias. Selection bias is unlikely given the high level of follow-up in terms of cases and subcohort person-years [22, 30] . In theory, selection bias may have occurred in the collection of tissue samples [31] . For 235 of the 337 cases (70%), tumour material could be collected. There was no indication for bias in the selection of cases with tumour material according to the risk factors and potential confounders studied, except for the use of antihypertensive medication, which can be attributed most likely to chance. Information bias is unlikely in our study because the information with respect to the risk factors was collected before the diagnosis of RCC. Diagnosis of hypertension and use of antihypertensive medication were self-reported, however, and misclassification of exposure is a potential source of bias. In two studies conducted in the USA moderate agreement between self-report and actual measurement of blood pressure was observed; estimates of sensitivity for self-reported hypertension were between 62 and 82% [32] and 71% in the NHANES III study [33] . In an American validation study, sensitivity of recall for use of antihypertensive medication among controls was 86% after 2 years and 79% after 8 years [34] . In a small validation study (207 subjects) within our cohort study, use of medication for the cardiovascular system was recalled correctly by 66% of the users [26] . The subgroup of cases and subcohort members that reported use of antihypertensive medication, without reporting a diagnosis of hypertension, may indicate misclassification. Examining the indications for medication reported by the participants in the questionnaire at baseline revealed that only 11% of the persons in this group reported that the medication was used because of hypertension, suggesting that misclassification is limited. The misclassification of self-reported hypertension and use of antihypertensive medication is expected to be non-differential, attenuating the rate ratios towards one.
In a meta-analysis [2] based on 13 case-control studies, a pooled adjusted odds ratio of 1.75 (95% CI, 1.61-1.90) was calculated for the association between hypertension and RCC. This pooled odds ratio did not include results from prospective cohort studies. Four prospective cohort studies measured blood pressure at baseline and followed the cohort members for the occurrence of RCC [5, 6, 9, 10] . All studies found increased risks of RCC with increasing blood pressure. The outcomes of these studies are difficult to compare with our study, because of the different exposure measurement. Three prospective cohort studies used self-reported diagnosis of hypertension to define the exposure [8, 11, 12] and show therefore the highest resemblance with our study design. Two of these studies reported increased RRs for diagnosis of hypertension and RCC risk [11, 12] . These studies were relatively small, however, with 14 and 62 RCC cases, respectively. The Cancer Prevention Study II [8] included 1.2 million subjects and 335 RCC deaths after 7 years of follow-up. Self-reported diagnosis of hypertension was associated with RCC deaths in females (RR, 2.2; 95% CI, 1.5-3.2), but not in males (RR, 1.1; 95% CI, 0.9-1.5) [8] . The RRs for hypertension observed in the current study are lower than the pooled odds ratio for case-control studies [2] , but our estimates point in the same direction. Also, several other studies have published RRs comparable to ours, especially for males [4, 8, [35] [36] [37] .
In another meta-analysis, a pooled odds ratio was calculated for use of diuretics and risk of RCC [1] . Based on nine case-control studies, an average odds ratio was calculated of 1.55 (95% CI, 1.42-1.71). Some of the included studies used self-report, while others used medical files or data from a pharmacy database [4, 36, 38, 39] . Three prospective cohort studies also showed an increased risk for use of diuretics, with an exception for males in the Cancer Prevention Study II [7, 8, 11] .
Hypertension may be a possible cause, but it may also be an early symptom of RCC [40] . The increased risk of hypertension may therefore reflect detection bias. Whether this bias is present may be evaluated by excluding cases from the analysis that were detected shortly after baseline measurement, or by investigating the relative risks according to time interval between diagnosis of hypertension and baseline. In our study, relative risks were slightly lower after exclusion of cases in the first 2 years of follow-up, and duration between diagnosis of hypertension and baseline was associated with slightly decreasing risks estimates. In a Danish record-linkage study [7] a U-shaped pattern was observed, with highest risks for the shortest and the longest time intervals. Other studies did not observe a modification of the risk estimates according to time interval [4, 10, 38, 41, 42] .
Despite the large number of epidemiological studies, there is little convincing evidence with respect to the biological mechanism between hypertension or use of antihypertensive medication and the development of RCC. Gago-Dominguez et al. [18] suggested that lipid peroxidation, which is increased in obese and hypertensive individuals, might be responsible -at least in partfor the increased risk of RCC. By-products of lipid peroxidation have been shown to react with renal DNA to form adducts [18] . Diuretic therapy might be carcinogenic through conversion in the stomach to carcinogenic nitroso derivates or through a low-grade carcinogenic effect on the renal tubular cell, its principal target [1] .
In our study, we also investigated whether hypertension and/or use of antihypertensive medication were associated with mutational status of the VHL gene. The VHL gene is a tumour suppressor gene. Loss of function is an early event in most cases of clear-cell RCC, by mutation or methylation of the promoter region. When hypertension and/or use of antihypertensive drugs are related to RCC risk, it is conceivable that these risk factors are associated with specific subtypes of RCC, e.g. clear-cell RCC with mutations in the VHL gene. In our analysis somewhat higher risks were found for hypertension in relation to the risk of clear-cell RCC with a mutation in the VHL gene, and slightly decreased risks in cases with VHL wild type. For use of antihypertensive medication and especially diuretic treatment, we observed the opposite; RRs were increased in cases with VHL wild type and only slightly increased in cases with mutations in the VHL gene. It is possible that diagnosis of hypertension and use of diuretics and risk of clear-cell RCC work through different pathways (through a mutation in the VHL gene or not). However, false-positive findings because of multiple testing and small numbers cannot be excluded.
This is the first study to evaluate the association of hypertension and/or use of antihypertensive medication with mutations in the VHL gene. Without a specific a priori hypothesis it is difficult to exclude chance findings, especially with the small numbers in the subanalyses. The findings with respect to the possible association with the VHL gene need to be confirmed in future studies.
